Osmessn.com

Image Credit: Adobe Stock Images/Thanayut.com Goodpath, a virtual clinic for chronic health conditions, has reached a pharmacy integration deal with GiftHealth, Eli Lilly and Company’s LillyDirect pharmacy provider.1 LillyDirect is Lilly’s direct-to-consumer digital healthcare platform that was launched back in January 2024.2 It’s known for providing resources for disease management, featuring access to independent healthcare providers, support, and […]

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply chain resilience and quality control, […]

Mike Hennessy Jr, chairman and CEO, MJH Life Sciences Every stakeholder’s role in the pharmaceutical supply chain is just as important as the next, and that certainly holds true for that of the drug wholesaler. Essentially, these businesses serve as an intermediary between manufacturers and the downstream chain—after buying medications in bulk from manufacturers, they […]

View the Pharmaceutical Commerce August 2025 issue in an interactive format.

340B: Recent Timeline July 31, 2025: HRSA launches 340B Rebate Model Pilot. The US Health Resources & Services Administration (HRSA) formally opened a voluntary Rebate Model Pilot Program, inviting select drugmakers to apply to implement retrospective rebates—instead of upfront discounts—for 340B drugs included in the Medicare negotiated price list. Public comments are being accepted through […]

In a video interview with Pharma Commerce, Mark Lee, MarqVision’s founder and CEO, highlights the rapid growth and increasing sophistication of the counterfeit pharmaceutical market, driven in large part by bad actors leveraging artificial intelligence (AI). Counterfeiters are now using AI to replicate authentic pharmaceutical packaging with high accuracy, build convincing fake websites, and manipulate […]

Key Takeaways Pharma brands should evaluate AI in patient services by asking outcome-focused questions—how it improves patient care and brand performance—not just how it reduces costs. Effective AI solutions should preserve human touchpoints, have clear escalation paths when automation fails, and maintain strict data governance to protect patient information. Access leaders must ensure AI is […]

In a video interview with Pharma Commerce, Dave Malenfant, a healthcare supply chain expert, discusses the potential impact of a proposed 250% tariff on pharmaceutical imports, emphasizing that the effect depends heavily on where in the supply chain the tariff is applied. If imposed on active pharmaceutical ingredients (APIs), the impact would be minimal, as […]

Key Takeaways Patient access to treatment remains poor. For the second year in a row, patients with chronic conditions rated health plan access a “D,” with nearly half facing insurance-related barriers like high cost-sharing, formulary restrictions, and prior authorization. Barriers are worsening in 2025. Over a third of chronically ill adults have faced treatment access […]

In a video interview with Pharma Commerce, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, he describes how the One Big Beautiful Bill Act (OBBBA) is expected to significantly influence prescription drug spending by reshaping access and reimbursement within Medicaid, certain Medicare segments, and ACA exchange plans. The OBBBA introduces pressure on pharmaceutical revenues, particularly by […]

Image Credit: Adobe Stock Images/DavideBonaldo.com Last week, President Trump issued letters to 17 of the largest pharmaceutical companies, expressing dire urgency for making changes along the drug pricing front.1 These letters date back to an executive order (EO) he enacted in May that essentially proclaimed that pharma companies need to treat the United States as a […]

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of US supply chain, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as Zenk notes, “all healthcare is local.” Patients want […]

In a video interview with Pharma Commerce, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, he describes how the One Big Beautiful Bill Act (OBBBA) is expected to significantly influence prescription drug spending by reshaping access and reimbursement within Medicaid, certain Medicare segments, and ACA exchange plans. The OBBBA introduces pressure on pharmaceutical revenues, particularly by […]

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of US supply chain, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as Zenk notes, “all healthcare is local.” Patients want […]

In a video interview with Pharma Commerce, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, he describes how the One Big Beautiful Bill Act (OBBBA) is expected to significantly influence prescription drug spending by reshaping access and reimbursement within Medicaid, certain Medicare segments, and ACA exchange plans. The OBBBA introduces pressure on pharmaceutical revenues, particularly by […]

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of supply chain operations & distribution services, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as Zenk notes, “all healthcare is […]